RG2833Brain-penetrant HDAC inhibitor CAS# 1215493-56-3 |
- Resminostat hydrochloride
Catalog No.:BCC1888
CAS No.:1187075-34-8
- Rocilinostat (ACY-1215)
Catalog No.:BCC2144
CAS No.:1316214-52-4
- Daminozide
Catalog No.:BCC1514
CAS No.:1596-84-5
- Tasquinimod
Catalog No.:BCC1987
CAS No.:254964-60-8
- CHAPS
Catalog No.:BCC1476
CAS No.:75621-03-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1215493-56-3 | SDF | Download SDF |
| PubChem ID | 56654642 | Appearance | Powder |
| Formula | C20H25N3O2 | M.Wt | 339.43 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | RGFP109 | ||
| Solubility | DMSO : ≥ 50 mg/mL (147.31 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide | ||
| SMILES | CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N | ||
| Standard InChIKey | VOPDXHFYDJAYNS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H25N3O2/c1-15-10-12-16(13-11-15)20(25)22-14-6-2-3-9-19(24)23-18-8-5-4-7-17(18)21/h4-5,7-8,10-13H,2-3,6,9,14,21H2,1H3,(H,22,25)(H,23,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | RG2833 is a brain-penetrant inhibitor of HDAC with IC50 values of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. | |||||
| Targets | HDAC1 | HDAC3 | ||||
| IC50 | 60 nM | 50 nM | ||||
RG2833 Dilution Calculator
RG2833 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9461 mL | 14.7306 mL | 29.4612 mL | 58.9223 mL | 73.6529 mL |
| 5 mM | 0.5892 mL | 2.9461 mL | 5.8922 mL | 11.7845 mL | 14.7306 mL |
| 10 mM | 0.2946 mL | 1.4731 mL | 2.9461 mL | 5.8922 mL | 7.3653 mL |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5892 mL | 1.1784 mL | 1.4731 mL |
| 100 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.5892 mL | 0.7365 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
RG2833 is a histone deacetylase (HDAC) inhibitor.
In the neuronal cell, RG2833 increased Friedreich Ataxia (FXN) mRNA and protein levels, with concomitant changes in the epigenetic state of the gene. In PBMCs, RG2833 inhibited HDAC expression and increased H3K9 acetylation, and increased FXN mRNA in blood from patients.
In iPSC-derived neuronal cell model, plasma RG2833 (5μM) inhibited maximal deacetylase and upregulated FXN. The result showed a good correlation between increase in FXN transcript and inhibition of deacetylase activity, providing evidence that the mechanism of action of RG2833 is through deacetylation. [1]
Reference:
1.Soragni E, Miao W, Iudicello M et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol. 2014 Oct;76(4):489-508.
- GR 144053 trihydrochloride
Catalog No.:BCC6998
CAS No.:1215333-48-4
- SR 58611A hydrochloride
Catalog No.:BCC7833
CAS No.:121524-09-2
- Salvianolic acid B; Lithospermic acid B; Danfensuan B
Catalog No.:BCC8249
CAS No.:121521-90-2
- PF-04991532
Catalog No.:BCC8094
CAS No.:1215197-37-7
- 5-Benzyloxyindole
Catalog No.:BCC8742
CAS No.:1215-59-4
- Daclatasvir (BMS-790052)
Catalog No.:BCC2533
CAS No.:1214735-16-6
- Ajugapantin A
Catalog No.:BCN3663
CAS No.:121449-67-0
- WZ4003
Catalog No.:BCC4363
CAS No.:1214265-58-3
- WZ8040
Catalog No.:BCC1075
CAS No.:1214265-57-2
- WZ3146
Catalog No.:BCC4004
CAS No.:1214265-56-1
- POM 1
Catalog No.:BCC7454
CAS No.:12141-67-2
- N6-Benzyladenine
Catalog No.:BCC9076
CAS No.:1214-39-7
- CFM 1571 hydrochloride
Catalog No.:BCC5924
CAS No.:1215548-30-3
- SB 242084
Catalog No.:BCC5949
CAS No.:1215566-78-1
- RS 100329 hydrochloride
Catalog No.:BCC5741
CAS No.:1215654-26-4
- CP-809101 hydrochloride
Catalog No.:BCC1499
CAS No.:1215721-40-6
- NBI 27914 hydrochloride
Catalog No.:BCC7124
CAS No.:1215766-76-9
- Gatifloxacin hydrochloride
Catalog No.:BCC4224
CAS No.:121577-32-0
- DMCM hydrochloride
Catalog No.:BCC7560
CAS No.:1215833-62-7
- Valspodar
Catalog No.:BCC2027
CAS No.:121584-18-7
- 6-Demethoxy-9'-deoxycleomiscosin A
Catalog No.:BCN7298
CAS No.:121587-18-6
- 6-Demethoxycleomiscosin A
Catalog No.:BCN7299
CAS No.:121587-20-0
- YM 298198 hydrochloride
Catalog No.:BCC7366
CAS No.:1216398-09-2
- SB 258585 hydrochloride
Catalog No.:BCC7216
CAS No.:1216468-02-8
Epigenetic therapy for Friedreich ataxia.[Pubmed:25159818]
Ann Neurol. 2014 Oct;76(4):489-508.
OBJECTIVE: To investigate whether a histone deacetylase inhibitor (HDACi) would be effective in an in vitro model for the neurodegenerative disease Friedreich ataxia (FRDA) and to evaluate safety and surrogate markers of efficacy in a phase I clinical trial in patients. METHODS: We used a human FRDA neuronal cell model, derived from patient induced pluripotent stem cells, to determine the efficacy of a 2-aminobenzamide HDACi (109) as a modulator of FXN gene expression and chromatin histone modifications. FRDA patients were dosed in 4 cohorts, ranging from 30mg/day to 240mg/day of the formulated drug product of HDACi 109, RG2833. Patients were monitored for adverse effects as well as for increases in FXN mRNA, frataxin protein, and chromatin modification in blood cells. RESULTS: In the neuronal cell model, HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with concomitant changes in the epigenetic state of the gene. Chromatin signatures indicate that histone H3 lysine 9 is a key residue for gene silencing through methylation and reactivation through acetylation, mediated by the HDACi. Drug treatment in FRDA patients demonstrated increased FXN mRNA and H3 lysine 9 acetylation in peripheral blood mononuclear cells. No safety issues were encountered. INTERPRETATION: Drug exposure inducing epigenetic changes in neurons in vitro is comparable to the exposure required in patients to see epigenetic changes in circulating lymphoid cells and increases in gene expression. These findings provide a proof of concept for the development of an epigenetic therapy for this fatal neurological disease.
